Aidan Patrick McLinden
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Aidan Patrick McLinden has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
- Vibha N. Lama
Department of Medicine, Emory University, Atlanta, GA, USA
3 shared publications - Natalie M. Walker
Division of Pulmonary and Critical Care Medicine, University of Michigan Medical School, Ann Arbor, United States of America
2 shared publications - Ragini Vittal
Emory University School of Medicine
2 shared publications - Alison M. Lock
Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA
1 shared publication - Amanda Lee Garner
Department of Medicinal Chemistry, College of Pharmacy, University of Michigan, Ann Arbor, Michigan 48109, United States
1 shared publication Carol F. Farver
Cleveland Clinic
1 shared publication
Latest Publications
- Open Access
Characterization of bronchovascular-bundle mesenchymal stromal cells regulating antibody-secreting cell niche in rejecting lung allografts
A transplanted lung offers a permissive milieu for local adaptive immune cell responses. Here, we characterize a transcriptionally and anatomically distinct adult lung-resident mesenchymal stromal population (MSC) that supports a pro-survival niche for antibody-secreting cells in rejecting lung allografts through a novel IL-6 trans-signaling/CXCL12 axis. By using a mouse orthotopic lung transplant model and Blimp1YFP recipients, we identify spatial localization of antibody-secreting cells (ASCs) and terminally differentiated plasma cells (PCs) along the bronchovascular bundles (BVBs). A previously described Foxf1+/Gli1+/Itga8-subset of collagen-expressing MSCs, which forms a 3-dimensional network along the bronchovascular bundles (BVB-MSCs), was found to be the major source of the PC survival factors CXCL12 and IL6. Cxcl12iCre/ERT2R26RtdTomato mice utilized as donors validated the expansion of this population in a rejecting graft and their intimate association with ASCs. CXCL12 expression was increased in allografts and Foxf1+ MSCs isolated from human CLAD patients. IL6 trans signaling/STAT3 signaling axis was shown to upregulate CXCL12 secretion in human MSCs, and Olamkicept-mediated neutralization of IL6 trans-signaling in murine RAS attenuates CXCL12 expression, intra-graft ASC population, and fibrogenesis. Our findings represent the first delineation of specialized CXCL12-expressing stromal cells in adult lungs and demonstrate their contribution to sustaining intragraft ASC niches and allograft fibrogenesis.
Open AccessCharacterization of bronchovascular-bundle mesenchymal stromal cells regulating antibody-secreting cell niche in rejecting lung allografts
A transplanted lung offers a permissive milieu for local adaptive immune cell responses. Here, we characterize a transcriptionally and anatomically distinct adult lung-resident mesenchymal stromal population (MSC) that supports a pro-survival niche for antibody-secreting cells in rejecting lung allografts through a novel IL-6 trans-signaling/CXCL12 axis. By using a mouse orthotopic lung transplant model and Blimp1YFP recipients, we identify spatial localization of antibody-secreting cells (ASCs) and terminally differentiated plasma cells (PCs) along the bronchovascular bundles (BVBs). A previously described Foxf1+/Gli1+/Itga8-subset of collagen-expressing MSCs, which forms a 3-dimensional network along the bronchovascular bundles (BVB-MSCs), was found to be the major source of the PC survival factors CXCL12 and IL6. Cxcl12iCre/ERT2R26RtdTomato mice utilized as donors validated the expansion of this population in a rejecting graft and their intimate association with ASCs. CXCL12 expression was increased in allografts and Foxf1+ MSCs isolated from human CLAD patients. IL6 trans signaling/STAT3 signaling axis was shown to upregulate CXCL12 secretion in human MSCs, and Olamkicept-mediated neutralization of IL6 trans-signaling in murine RAS attenuates CXCL12 expression, intra-graft ASC population, and fibrogenesis. Our findings represent the first delineation of specialized CXCL12-expressing stromal cells in adult lungs and demonstrate their contribution to sustaining intragraft ASC niches and allograft fibrogenesis.
- Open Access
- 15 August 2024
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 134 (16)
MNK-driven eIF4E phosphorylation regulates the fibrogenic transformation of mesenchymal cells and chronic lung allograft dysfunction
Tissue fibrosis remains unamenable to meaningful therapeutic interventions and is the primary cause of chronic graft failure after organ transplantation. Eukaryotic translation initiation factor (eIF4E), a key translational regulator, serves as convergent target of multiple upstream profibrotic signaling pathways that contribute to mesenchymal cell (MC) activation. Here, we investigate the role of MAP kinase–interacting serine/threonine kinase–induced (MNK-induced) direct phosphorylation of eIF4E at serine 209 (Ser209) in maintaining fibrotic transformation of MCs and determine the contribution of the MNK/eIF4E pathway to the pathogenesis of chronic lung allograft dysfunction (CLAD). MCs from patients with CLAD demonstrated constitutively higher eIF4E phosphorylation at Ser209, and eIF4E phospho-Ser209 was found to be critical in regulating key fibrogenic protein autotaxin, leading to sustained β-catenin activation and profibrotic functions of CLAD MCs. MNK1 signaling was upregulated in CLAD MCs, and genetic or pharmacologic targeting of MNK1 activity inhibited eIF4E phospho-Ser209 and profibrotic functions of CLAD MCs in vitro. Treatment with an MNK1/2 inhibitor (eFT-508) abrogated allograft fibrosis in an orthotopic murine lung-transplant model. Together these studies identify what we believe is a previously unrecognized MNK/eIF4E/ATX/β-catenin signaling pathway of fibrotic transformation of MCs and present the first evidence, to our knowledge, for the utility of MNK inhibitors in fibrosis.
- 15 August 2024
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 134 (16)
Open AccessMNK-driven eIF4E phosphorylation regulates the fibrogenic transformation of mesenchymal cells and chronic lung allograft dysfunction
Tissue fibrosis remains unamenable to meaningful therapeutic interventions and is the primary cause of chronic graft failure after organ transplantation. Eukaryotic translation initiation factor (eIF4E), a key translational regulator, serves as convergent target of multiple upstream profibrotic signaling pathways that contribute to mesenchymal cell (MC) activation. Here, we investigate the role of MAP kinase–interacting serine/threonine kinase–induced (MNK-induced) direct phosphorylation of eIF4E at serine 209 (Ser209) in maintaining fibrotic transformation of MCs and determine the contribution of the MNK/eIF4E pathway to the pathogenesis of chronic lung allograft dysfunction (CLAD). MCs from patients with CLAD demonstrated constitutively higher eIF4E phosphorylation at Ser209, and eIF4E phospho-Ser209 was found to be critical in regulating key fibrogenic protein autotaxin, leading to sustained β-catenin activation and profibrotic functions of CLAD MCs. MNK1 signaling was upregulated in CLAD MCs, and genetic or pharmacologic targeting of MNK1 activity inhibited eIF4E phospho-Ser209 and profibrotic functions of CLAD MCs in vitro. Treatment with an MNK1/2 inhibitor (eFT-508) abrogated allograft fibrosis in an orthotopic murine lung-transplant model. Together these studies identify what we believe is a previously unrecognized MNK/eIF4E/ATX/β-catenin signaling pathway of fibrotic transformation of MCs and present the first evidence, to our knowledge, for the utility of MNK inhibitors in fibrosis.
- 26 November 2022
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 42 (3) , 317-326
The mitigating effect of exogenous carbon monoxide on chronic allograft rejection and fibrosis post-lung transplantation
- 26 November 2022
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 42 (3) , 317-326
The mitigating effect of exogenous carbon monoxide on chronic allograft rejection and fibrosis post-lung transplantation